Improved oral bioavailability of human growth hormone by a combination of liposomes containing bio-enhancers and tetraether lipids and omeprazole

Journal of Pharmaceutical Sciences

Volumn 103, Issue 12, 2014, Pages 3985-3993

  Parmentier, Johannes ^a   Hofhaus, Götz ^a   Thomas, Silke ^b   Cuesta, Laura Clusa ^a   Gropp, Felix ^c   Schröder, Rasmus ^a   Hartmann, Klaus ^b   Fricker, Gert ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b Praxis für Pädiatrische Endokrinologie and Diabetologie   (Germany)

^c Bernina Plus GmbH   (Germany)

Author keywords

Archae; Dual asymmetric centrifugation; Imaging methods; Lipogelosomes; Liposomes; Oral absorption; Permeation enhancers; Proteins

Indexed keywords

1 PHENYLPIPERAZINE DERIVATIVE; CETYLPYRIDINIUM SALT; HUMAN GROWTH HORMONE; LIPOSOME; OCTADECANETHIOL; OMEPRAZOLE; PENETRATION ENHANCING AGENT; SODIUM CAPRATE; TOCOFERSOLAN; UNCLASSIFIED DRUG; LIPID;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONFOCAL LASER MICROSCOPY; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG FORMULATION; DRUG PENETRATION; DUODENUM; EX VIVO STUDY; IN VITRO STUDY; IN VIVO STUDY; INTESTINE MUCOSA; JEJUNUM; LIPOSOMAL DELIVERY; MALE; NONHUMAN; PARTICLE SIZE; PLASMA CONCENTRATION-TIME CURVE; RAT; SMALL INTESTINE; ZETA POTENTIAL; ANIMAL; BIOAVAILABILITY; CHEMISTRY; HUMAN; MEDICINAL CHEMISTRY; METABOLISM; ORAL DRUG ADMINISTRATION; PROCEDURES; WISTAR RAT;

ADMINISTRATION, ORAL; ANIMALS; BIOLOGICAL AVAILABILITY; CHEMISTRY, PHARMACEUTICAL; DUODENUM; HUMAN GROWTH HORMONE; HUMANS; INTESTINAL MUCOSA; JEJUNUM; LIPIDS; LIPOSOMES; MALE; OMEPRAZOLE; RATS; RATS, WISTAR;

EID: 84914814600     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.24215     Document Type: Article

References (62)

1. Malik DK, Baboota S, Ahuja A, Hasan S, Ali J. 2007. Recent advances in protein and peptide drug delivery systems. Curr Drug Deliv 4(2):141-151.
2. Singh R, Singh S, Lillard JW. 2008. Past, present, and future technologies for oral delivery of therapeutic proteins. J Pharm Sci 97(7):2497-2523.
3. Kumar TRS, Soppimath K, Nachaegari SK. 2006. Novel delivery technologies for protein and peptide therapeutics. Curr Pharm Biotechnol 7(4):261-276.
4. Fricker G, Drewe J. 1996. Current concepts in intestinal peptide absorption. J Pept Sci 2(4):195-211.
5. Hamman J, Enslin G, Kotzé A. 2006. Oral delivery of peptide drugs: Barriers and developments. Bio Drugs 19(3):165-177.
6. Stoll BR, Leipold HR, Milstein S, Edwards DA. 2000. A mechanistic analysis of carrier-mediated oral delivery of protein therapeutics. J Control Release 64(1-3):217-228.
7. Malkov D, Angelo R, Wang H-z, Flanders E, Tang H, Gomez-Orellana I. 2005. Oral delivery of insulin with the eligen technology: Mechanistic studies. Curr Drug Deliv 2(2):191-197.
8. des Rieux A, Fievez V, Garinot M, Schneider Y-J, Préat V. 2006. Nanoparticles as potential oral delivery systems of proteins and vaccines: A mechanistic approach. J Control Release 116(19):1-27.
9. Thirawong N, Thongborisute J, Takeuchi H, Sriamornsak P. 2008. Improved intestinal absorption of calcitonin by mucoadhesive delivery of novel pectin-liposome nanocomplexes. J Control Release 125(3):236-245.
10. Yamabe K. 2003. Potentiality of double liposomes containing salmon calcitonin as an oral dosage form. J Control Release 89(3):429-436.
11. Kadir A, Mokhtar MTM, Wong TW. 2013. Nanoparticulate assembly of mannuronic acid- and guluronic acid-rich alginate: Oral insulin carrier and glucose binder. J Pharm Sci 102(12):4353-4363.
12. Jesorka A, Orwar O. 2008. Liposomes: Technologies and analytical applications. Annu Rev Anal Chem 1:801-832.
13. Kraft JC, Freeling JP, Wang Z, Ho RJY. 2014. Emerging research and clinical development trends of liposome and lipid nanoparticle drug delivery systems. J Pharm Sci 103(1):29-52.
14. Fricker G, Kromp T, Wendel A, Blume A, Zirkel J, Rebmann H, Setzer C, Quinkert R-O, Martin F, Müller-Goymann C. 2010. Phospholipids and lipid-based formulations in oral drug delivery. Pharm Res 27(8):1469-1486.
15. Muramatsu K, Maitani Y, Nagai T. 1996. Dipalmitoylphosphatidylcholine liposomes with soybean-derived sterols and cholesterol as a carrier for the oral administration of insulin in rats. Biol Pharm Bull 19(8):1055-1058.
16. Choquet CG, Patel GB, Beveridge TJ, Sprott GD. 1994. Stability of pressure-extruded liposomes made from archaeobacterial ether lipids. Appl Microbiol Biotechnol 42(2-3):375-384.
17. Filipović-Grcić J, Skalko-Basnet N, Jalsenjak I. 2001. Mucoadhesive chitosan-coated liposomes: Characteristics and stability. J Microencapsul 18(1):3-12.
18. Szoka F, Papahadjopoulos D. 1980. Comparative properties and methods of preparation of lipid vesicles (liposomes). Annu Rev Biophys Bioeng 9:467-508.
19. Brandl M, Drechsler M, Bachmann D, Bauer K. 1997. Morphology of semisolid aqueous phosphatidylcholine dispersions, a freeze fracture electron microscopy study. Chem Phys Lipids 87(1):65-72.
20. Brandl M. 2007. Vesicular phospholipid gels: A technology platform. J Liposome Res 17(1):15-26.
21. Massing U, Cicko S, Ziroli V. 2008. Dual asymmetric centrifugation (DAC) - A new technique for liposome preparation. J Control Release 125(1):16-24.
22. Tian W, Schulze S, Brandl M, Winter G. 2009. Vesicular phospholipid gel-based depot formulations for pharmaceutical proteins: Development and in vitro evaluation. J Control Release 142(3):319-325.
23. Parmentier J, Hartmann FJ, Fricker G. 2010. In vitro evaluation of liposomes containing bio-enhancers for the oral delivery of macromolecules. Eur J Pharm Biopharm 76:394-403.
24. Parmentier J, Becker MM, Heintz U, Fricker G. 2011. Stability of liposomes containing bio-enhancers and tetraether lipids in simulated gastro-intestinal fluids. Int J Pharm 405:210-217.
25. Takeda A, Cooper K, Bird A, Baxter L, Frampton GK, Gospodarevskaya E, Welch K, Bryant J. 2010. Recombinant human growth hormone for the treatment of growth disorders in children: A systematic review and economic evaluation. Health Technol Assess 14(42):1-209.
26. Hirsch M, Ziroli V, Helm M, Massing U. 2009. Preparation of small amounts of sterile siRNA-liposomes with high entrapping efficiency by dual asymmetric centrifugation (DAC). J Control Release 135(1):80-88.
27. Mahato R, Narang A, Thoma L, Miller D. 2003. Emerging trends in oral delivery of peptide and protein drugs. Crit Rev Ther Drug 20(2-3):153-214.
28. Wang J, Yadav V, Parry A, Tajiri S, Basit AW. 2013. Stability of peptide drugs in simulated gastric and intestinal fluids. 2013 AAPS Annual Meeting and Exposition, http://abstracts.aaps.org/Verify/aaps2013/postersubmissions/W4284.pdf 10/11/2014.
29. Wang J, Yadav V, Parry A, Tajiri S, Basit AW. 2013. Stability of 17 peptide drugs in the gastrointestinal tract of pigs. 2013 AAPS Annual Meeting and Exposition, http://abstracts.aaps.org/Verify/aaps2013/postersubmissions/R6013.pdf 10/11/2014.
30. Wang J, Yadav V, Parry A, Tajiri S, Basit AW. 2013. Colonic stability of peptide drugs. 2013 AAPS Annual Meeting and Exposition, http://abstracts.aaps.org/Verify/aaps2013/postersubmissions/T3079.pdf 10/11/2014.
31. Lipinski C, Lombardo F, Dominy B, Feeney P. 1997. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev 23(1-3):3-25.
32. Mustata G, Dinh SM. 2006. Approaches to oral drug delivery for challenging molecules. Crit Rev There Drug 23(2):111-135.
33. Patel HM, Stevenson RW, Parsons JA, Ryman BE. 1982. Use of liposomes to aid intestinal absorption of entrapped insulin in normal and diabetic dogs. Biochim Biophys Acta 716(2):188-193.
34. Chiang C, Weiner N. 1987. Gastrointestinal uptake of liposomes. II: In vivo studies. Int J Pharm 40(1-2):143-150.
35. Parmentier J, Thewes B, Gropp F, Fricker G. 2011. Oral peptide delivery by tetraether lipid liposomes. Int J Pharm 415(1-2):150-157.
36. Jacquemet A, Barbeau J, Lemiegre L, Benvegnu T. 2009. Archaeal tetraether bipolar lipids: Structures, functions and applications. Biochimie 91(6):711-717.
37. Patel GB, Chen W. 2005. Archaeosome immunostimulatory vaccine delivery system. Curr Drug Deliv 2(4):407-421.
38. Li Z, Chen J, Sun W, Xu Y. 2010. Investigation of archaeosomes as carriers for oral delivery of peptides. Biochem Biophys Res Commun 394(2):412-417.
39. Paula S, Volkov AG, Hoek ANV, Haines TH, Deamer DW. 1996. Permeation of protons, potassium ions, and small polar molecules through phospholipid bilayers as a function of membrane thickness. Biophys J 70(1):339-348.
40. van Winden EC. 2003. Freeze-drying of liposomes: Theory and practice. Meth Enzymol 367:99-110.
41. Hauton J, Charbonnier M, Cara L, Salles J. 1994. A new-type of liposome for electrochemical treatment of cancer - The lipogelosomes. Eur J Surg (574):117-119.
42. Deʇim IT, Gümüşel B, Deʇim Z, Ozc¸elikay T, Tay A, Güner S. 2006. Oral administration of liposomal insulin. J Nanosci Nanotechnol 6(9-10):2945-2949.
43. O'Hagan DT. 1996. The intestinal uptake of particles and the implications for drug and antigen delivery. J Anat 189(3):477-482.
44. Aungst BJ. 2000. Intestinal permeation enhancers. J Pharm Sci 25(8):429-442.
45. Kondoh M, Yagi K. 2007. Progress in absorption enhancers based on tight junction. Exp Opin Drug Deliv 4(3):275-286.
46. Niu M, Lu Y, Hovgaard L, Guan P, Tan Y, Lian R, Qi J, Wu W. 2012. Hypoglycemic activity and oral bioavailability of insulin-loaded liposomes containing bile salts in rats: The effect of cholate type, particle size and administered dose. Eur J Pharm Biopharm 81(2):265-272.
47. Degim Z, Unal N, Essiz D, Abbasoglu U. 2004. The effect of various liposome formulations on insulin penetration across Caco-2 cell monolayer. Life Sci 75(23):2819-2827.
48. Song K, Chung S, Shim C. 2005. Enhanced intestinal absorption of salmon calcitonin (sCT) from proliposomes containing bile salts. J Control Release 106(3):298-308.
49. Shimazaki T, Tomita M, Sadahiro S, Hayashi M, Awazu S. 1998. Absorption-enhancing effects of sodium caprate and palmitoyl carnitine in rat and human colons. Digest Dis Sci 43(3):641-645.
50. Maher S, Leonard TW, Jacobsen J, Brayden DJ. 2009. Safety and efficacy of sodium caprate in promoting oral drug absorption: From in vitro to the clinic. Adv Drug Deliv Rev 61(15):1427-1449.
51. Bzik V, Brayden DJ. 2009. Permeating-enhancing and cytotoxic effects of 1-phenylpiperazine in isolated rat colonic mucosa. CRS Meeting:1-2.
52. Lai SK, Wang Y-Y, Wirtz D, Hanes J. 2009. Micro- and macrorheology of mucus. Adv Drug Deliv Rev 61(2):86-100.
53. Lai SK, Wang Y-Y, Hanes J. 2009. Mucus-penetrating nanoparticles for drug and gene delivery to mucosal tissues. Adv Drug Deliv Rev 61(2):158-171.
54. Lai SK, Wang Y-Y, Hida K, Cone R, Hanes J. 2010. Nanoparticles reveal that human cervicovaginal mucus is riddled with pores larger than viruses. P Natl Acad Sci USA 107(2):598-603.
55. Ensign LM, Tang BC, Wang Y-Y, Tse TA, Hoen T, Cone R, Hanes J. 2012. Mucus-penetrating nanoparticles for vaginal drug delivery protect against herpes simplex virus. Sci Transl Med 4(138):138-179.
56. Makhlof A, Werle M, Tozuka Y, Takeuchi H. 2011. A mucoadhesive nanoparticulate system for the simultaneous delivery of macromolecules and permeation enhancers to the intestinal mucosa. J Control Release 149(1):81-88.
57. Krauland AH, Guggi D, Bernkop-Schnurch A. 2004. Oral insulin delivery: The potential of thiolated chitosan-insulin tablets on nondiabetic rats. J Control Release 95(3):547-555.
58. Rowland RN, Woodley JF. 1981. Uptake of free and liposome-entrapped insulin by rat intestinal sacs in vitro. Biosci Rep 1(4):345-352.
59. Rowland RN, Woodley JF. 1981. Uptake of free and liposome-entrapped 125I-labelled PVP by rat intestinal sacs in vitro: Evidence for endocytosis. Biosci Rep 1(5):399-406.
60. Aramaki Y, Tomizawa H, Hara T, Yachi K, Kikuchi H, Tsuchiya S. 1993. Stability of liposomes in vitro and their uptake by rat Peyer's patches following oral administration. Pharm Res 10(8):1228-1231.
61. Werle M, Makhlof A, Takeuchi H. 2010. Carbopol-lectin conjugate coated liposomes for oral peptide delivery. Chem Pharm Bull 58(3):432-434.
62. Takeuchi H, Yamamoto H, Niwa T, Hino T, Kawashima Y. 1996. Enteral absorption of insulin in rats from mucoadhesive chitosan-coated liposomes. Pharm Res 13(6):896-901.